Dr. Albert Y. Hung, MD PHD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 551
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: Harvard Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
MA license 205706
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- Southcoast Hospitals Group Fall River, MA
- Cooley Dickinson Hospital Inc,the Northampton, MA
- Emerson Hospital - W Concord, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 551
- Services billed
- 1,153
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 347 | 242 |
| Established patient office or other outpatient visit, 30-39 minutes | 329 | 254 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 105 | 40 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 66 | 28 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 51 | 36 |
| New patient office or other outpatient visit, 60-74 minutes | 47 | 47 |
| Hospital discharge day management, 30 minutes or less | 33 | 33 |
| Established patient office or other outpatient visit, 20-29 minutes | 30 | 26 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 22 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Boston, MA | 1,087 |
| Carbidopa-Levodopa Er (carbidopa/levodopa) Other prescribers in Boston, MA | 383 |
| Rytary (carbidopa/levodopa) Other prescribers in Boston, MA | 256 |
| Amantadine (amantadine hcl) Other prescribers in Boston, MA | 198 |
| Gabapentin Other prescribers in Boston, MA | 136 |
| Quetiapine Fumarate Other prescribers in Boston, MA | 132 |
| Rasagiline Mesylate | 116 |
| Rivastigmine Other prescribers in Boston, MA | 112 |
| Trazodone Hcl Other prescribers in Boston, MA | 85 |
| Clonazepam Other prescribers in Boston, MA | 79 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $53,940 in research payments for these studies, mostly to the institutions running them.
- A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
UCB SA · Completed · NCT04658186 - An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
UCB SA · Terminated · NCT05543252
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.